What the FDA rules mean at a pharmacy
TB-500 has no FDA approval; its withdrawn nomination grants pharmacies no new permission.
You'll see the FDA's withdrawn-nomination entry, what it says about safety, and how prescription review differs from drug approval.
What does the FDA's TB-500 entry say now?
TB-500 is a short lab copy taken from the thymosin beta-4 protein. This page explains the FDA's withdrawn-nomination entry. The agency names TB-500 in its federal rules for pharmacy-made drugs [16][17]. I'd take that FDA page to your clinic if you hear a different claim.
The FDA's entry records a nomination that was withdrawn. TB-500 no longer sits in Category 2; the entry still warns of major safety concerns [17]. It warns that some ways of giving the drug could cause an immune reaction, such as rash or swelling, though it doesn't say the drug caused either one. The agency also says key safety facts are missing [17].
Some pharmacies may make a special drug for a patient named on a prescription; this is called compounding. The small form of thymosin beta-4 appears under "Bulk drug substances nominated but withdrawn"; this status supplies no new authorization for compounding [16][17]. The FDA also hasn't approved the small form for any illness [17]. A withdrawn nomination does not establish either FDA drug approval or permission to compound the ingredient [16][17].
These are general facts, not personal medical or legal advice. The site doesn't sell or supply it. If your clinic offers TB-500, ask which current FDA page permits the pharmacy to make it. Keep the answer with your health papers.
What can the 2026 FDA meeting notice tell you now?
The FDA notice used two chemical labels: "TB-500 (free base)" and "TB-500 acetate." They mean the ingredient was prepared in two forms; the notice doesn't say either form is safer or approved. The meeting date was July 23-24, 2026, and the question was whether pharmacies might use TB-500 as a raw ingredient [18]. Three other lab-made pieces were on the list, including BPC-157 [18].
A meeting notice isn't a final ruling [18]. An outside group of pharmacy experts can advise the FDA, but the FDA makes the rule [16]. The source used for this page was written before the meeting and doesn't report what happened. A claim about compounding permission needs a current FDA rule; the July meeting notice cannot supply one [16][18].
The current FDA page places TB-500 in the withdrawn-nomination table [17]. That table is separate from the Category 2 entries [17]. Its presence there establishes withdrawal, without granting permission to compound it [16][17]. The meeting notice records a scheduled discussion, not an FDA decision to place TB-500 on the compounding list [18].
What has to happen before a pharmacy makes medicine for you?
Federal law gives pharmacies two ways to make a drug that isn't sold ready-made. A licensed pharmacy or doctor may prepare medicine for the patient named on a prescription. An FDA-registered drug-making site may prepare larger batches [16]. Registration places that site under special FDA rules, yet not every ingredient becomes legal.
You must meet a licensed doctor or another clinician allowed to write prescriptions [16]. That person decides whether a pharmacy-made drug fits your care. Your pharmacy may fill your prescription, while a registered site can make larger amounts [16]. A video visit may count, but a valid prescription and true care relationship are still needed [16].
An ingredient needs separate legal support from an official U.S. drug book, an approved medicine, or the FDA's special list [16]. FDA records TB-500 as a withdrawn nomination and retains its safety cautions; the entry itself adds no permission for pharmacy use [16][17]. Even your lawful visit can't change the ingredient rule. The rule, rather than batch size, decides whether a pharmacy may use it.
This page doesn't point you to a clinic, pharmacy, or seller. It gives you no route around the law. If your clinic raises TB-500, ask who writes your prescription and which pharmacy fills it. Ask what your visit and medicine will cost before you agree.
Which TB-500 rules depend on where you live?
TB-500 isn't an FDA-approved drug for any human illness. The FDA now records a withdrawn nomination for TB-500, alongside the safety concerns it identified [16][17]. Sports rules are separate, and the world sports agency also bans it [15]. Laws outside the U.S. differ, so a local pharmacist or lawyer can explain the rule where you live.
What TB-500 questions can you ask a clinic about its pharmacy?
The small thymosin beta-4 form called TB-500 is listed by the FDA among withdrawn nominations [16][17]. It cited missing safety facts and the chance of an immune reaction with some ways of giving the drug. Withdrawal ends that nomination's evaluation for the compounding list; it grants no pharmacy permission [16][17]. The July 23-24, 2026 TB-500 meeting date has passed, but the source here was written before it and can't give the outcome [18].
Does your own prescription make TB-500 allowed?
A TB-500 prescription can follow clinical review, but it cannot by itself make a pharmacy ingredient eligible. The ingredient needs support from an official drug book, an approved medicine, or the FDA's special list [16]. The FDA's withdrawn-nomination entry does not grant pharmacies new authority to use TB-500 as a bulk ingredient [16][17]. Even an eligible drug requires your visit, your own prescription, and a licensed clinician who can write it [16].
Has the FDA approved TB-500 to treat an illness?
The answer is no: the FDA hasn't approved TB-500 for human use or any illness [17]. The FDA's TB-500 entry retains safety concerns even though the nomination is withdrawn [16][17]. Drug approval and permission for a pharmacy to make an ingredient aren't the same. A prescriber can consider a patient's request, while the pharmacy remains responsible for the rules governing its ingredients [16][17].
Can researchers study TB-500 when it isn't approved?
Yes, labs can study TB-500 even though the FDA hasn't approved it for any human illness [17]. The world sports agency bans the substance, while New Zealand and Australia treat it as prescription medicine [15]. A label reading "lab research only" doesn't give you permission to use the contents. This page reports what researchers gave people or animals; it doesn't grant treatment permission [17].